March 24, 2017 / 12:49 PM / 6 months ago

EMA panel backs Novo Nordisk's haemophilia B drug

(Reuters) - A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk’s (NOVOb.CO) haemophilia B drug.

The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Refixia, intended for the treatment and prevention of bleeding in patients 12 years and above with haemophilia B.

Haemophilia B is caused by the deficiency of the factor IX gene that is instrumental in blood clotting.

The panel’s opinion will now be reviewed by the EMA.

The positive recommendation comes at a time when Novo Nordisk struggles with declining sales from its aging diabetes franchise.

Last month, the Danish group warned that sales and profits might actually slip in 2017, a remarkable change in fortune for a company that was previously renowned for its sector-beating growth.

Outside diabetes, Novo Nordisk already has a significant blood products business focused on haemophilia.

Reporting by Rahul B in Bengaluru; Editing by Anil D'Silva

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below